Are Statistical Analysis Plans “required” for Pivotal Studies? [General Sta­tis­tics]

posted by Sereng  – USA, 2023-02-08 19:23 (465 d 17:23 ago) – Posting: # 23447
Views: 2,738

Dear colleagues, we are conducting a pivotal fed-fasted BE study versus a reference listed drug (RLD). In this case, by "pivotal", I mean the study will serve as the sole basis for (US) NDA approval. My CRO states that no "standalone" Statistical Analysis Plan (SAP) is required and that the statistical analysis in the protocol should suffice. However, the information in the protocol does not capture everything I would ordinarily expect to be in the SAP and I am not comfortable with the CRO's response. Is a (detailed) SAP required (or recommended), particularly where the entire NDA will be predicated on its findings?

Biostatistically Challenged CEO

Complete thread:

UA Flag
Activity
 Admin contact
23,029 posts in 4,834 threads, 1,644 registered users;
30 visitors (0 registered, 30 guests [including 6 identified bots]).
Forum time: 13:46 CEST (Europe/Vienna)

We must be careful not to confuse data with the abstractions
we use to analyze them.    William James

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5